"Dr. Wistinghausen On Developing Drugs For Children With Cancer"
Birte Wistinghausen, MD, medical director of the division of pediatric hematology-oncology at the Kravis Children’s Hospital and the Icahn School of Medicine at Mount Sinai, discusses developing drugs for children with cancer. Dr. Wistinghausen said that one of the challenges with developing drugs for children with cancer is access. New drugs are developed more frequently, and often introduced first, in adult patients. Most of the work being done in the early stages of development is attributed to the Children’s Oncology Group (COG) Phase I Consortium, Dr. Wistinghausen said. This is a very important group for COG, because they can test new drugs in a limited institution setting, and then move them very quickly to a group-wide setting.
- Birte Wistinghausen, MD, Medical Director, Division of Pediatric Hematology-Oncology, Kravis Children’s Hospital